	C 2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Total Revenue	677	931	1,208	1,474	1,734	1,983	2,126	2,055	2,588	2,890	3,341	3,743	4,209	4,648	5,453
Cost of Operating Revenue	268	349	404	417	462	481	485	467	785	798	1,012	1,247	1,251	1,271	1,428
Gross Profit	410	582	805	1,057	1,272	1,503	1,641	1,589	1,802	2,092	2,329	2,496	2,958	3,377	4,025
Gross Margin	60.5	62.5	66.6	71.7	73.3	75.8	77.2	77.3	69.6	72.4	69.7	66.7	70.3	72.6	73.8
Total Operating Expenses	552	741	883	1,020	1,183	1,316	1,519	1,552	1,992	1,997	2,529	3,062	3,156	3,520	4,126
Operating Profit	126	190	325	454	550	667	607	503	596	892	812	681	1,053	1,128	1,327
Operating Margin	18.5	20.4	26.9	30.8	31.7	33.7	28.6	24.5	23.0	30.9	24.3	18.2	25.0	24.3	24.3
Financing Income/(Expense) - Net	-35	-14	4	11	15	4	23	19	73	12	90	86	47	70	143
Profit before Taxes	91	177	330	456	559	648	623	514	664	900	909	745	1,114	1,189	1,378
Income Taxes	14	65	96	146	143	141	154	127	196	246	197	157	298	269	322
Profit after Tax	77	112	234	310	416	507	469	387	468	654	713	588	816	920	1,056
PAT Margin	11.4	12.0	19.4	21.0	24.0	25.6	22.0	18.8	18.1	22.6	21.3	15.7	19.4	19.8	19.4
EPS - Basic - ex Extraordinary Items	5.87	8.51	17.74	23.49	31.49	38.39	35.50	29.32	35.73	50.06	54.97	45.89	64.82	73.56	84.53
EPS - Diluted - ex Extraordinary Items	5.85	8.49	17.71	23.47	31.48	38.38	35.50	29.31	35.73	50.06	54.97	45.89	64.77	73.53	84.51
EBIT	126	190	325	454	550	667	607	503	596	892	812	681	1,053	1,128	1,327
EBITDA	157	225	369	505	595	729	667	575	691	1,008	937	811	1,188	1,273	1,500
EBITDA Margin	23.2	24.1	30.5	34.3	34.3	36.7	31.4	28.0	26.7	34.9	28.0	21.7	28.2	27.4	27.5

Balance Sheet

Abridged

Understanding Balance Sheet

Ajanta Pharma Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	340	369	520	621	763	851	1,224	1,181	1,642	2,028	2,264	2,825	2,731	2,843	3,735
Long-Term Investments	-	-	-	45	0	-	8	13	22	9	8	-	-	-	-
Property Plant & Equipment - Net	234	275	370	454	685	921	1,107	1,433	1,583	1,630	1,647	1,698	1,721	1,892	2,083
Total Non-Current Assets	309	349	429	522	725	997	1,225	1,515	1,677	1,751	1,791	1,854	1,907	2,172	2,419
Total Assets	649	718	949	1,143	1,488	1,848	2,449	2,696	3,319	3,779	4,056	4,679	4,638	5,015	6,155
Total Current Liabilities	250	222	275	185	260	247	346	378	606	649	647	1,139	895	996	1,416
Long Term Debt	76	73	52	33	15	1	1	1	13	20	19	26	24	35	39
Total Non-Current Liabilities	101	102	81	54	37	33	61	73	114	134	144	152	176	229	212
Total Liabilities	351	325	356	239	297	280	407	451	720	783	791	1,291	1,071	1,225	1,628
Total Shareholders' Equity	298	393	593	904	1,191	1,568	2,041	2,245	2,599	2,996	3,264	3,388	3,567	3,790	4,527
Total Equity	298	393	593	904	1,191	1,568	2,041	2,245	2,599	2,996	3,264	3,388	3,567	3,790	4,527
Total Liabilities & Equity	649	718	949	1,143	1,488	1,848	2,449	2,696	3,319	3,779	4,056	4,679	4,638	5,015	6,155

Cash Flow

Abridged

Understanding Cash Flow Statement

Ajanta Pharma Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	C 2013 Mar 31	R 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	110	178	288	361	456	583	537	469	577	779	756	723	909	1,005	1,215
Working Capital - Increase/(Decrease)	-55	39	-75	-82	-124	26	-254	-90	-123	-209	-200	67	-100	179	-653
Net CF from Operating Activities	55	216	213	280	332	609	283	378	453	570	556	790	809	1,184	562
Capital Expenditures - Net	60	91	131	104	297	296	263	342	234	170	130	165	139	317	360
Net CF from Investing Activities	-53	-105	-197	-165	-220	-384	-258	-227	-228	-284	-75	-560	38	-421	-474
Dividends Paid - Cash - Total	6	9	15	35	123	114	0	79	113	83	82	90	642	349	350
Stock - Issuance/(Retirement) - Net	-	-	0	0	0	-	-	-100	-	-135	-286	-	-388	-351	-
Debt - LT & ST - Issuance/(Retirement) - Total	9	-75	6	-58	22	-72	1	34	-6	-59	-16	-15	-16	-14	195
Net Cash Flow from Financing Activities	2	-85	-11	-99	-112	-200	0	-146	-121	-310	-453	-106	-1,048	-716	-155
Free Cash Flow to Equity	4	51	87	118	56	241	20	70	214	341	409	610	653	853	397
Free Operating CF net dividend	-11	116	64	141	-89	196	19	-44	101	316	325	526	14	517	-153
Free Operating CF	-5	125	79	176	34	310	20	35	214	398	407	615	656	866	197

Business Segment Analysis

FY End:

Mar 26

Ajanta Pharma Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceutcals (100.0%)₹ 365.16 Cr

Revenue / Sales

Pharmaceutcals (100.0%)₹ 5,452.86 Cr

Assets

Pharmaceutcals (100.0%)₹ 6,154.84 Cr

Operating Income

Pharmaceutcals (100.0%)₹ 1,326.60 Cr

Regional Segment Analysis

FY End:

Mar 26

Ajanta Pharma Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Emerging Market (37.7%)₹ 2,036.56 CrIndia (30.6%)₹ 1,653.85 CrUSA (28.8%)₹ 1,557.03 CrAfrica. (3.0%)₹ 159.82 Cr

Historical Segment Analysis

Track how Ajanta Pharma Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Pharmaceutcals	239	172	149	174	152	318	365

Frequently Asked Questions

What is the revenue of Ajanta Pharma Ltd.?

The latest trailing twelve month revenue of Ajanta Pharma Ltd. is ₹ 5,452.86 Cr, reflecting a 1-year growth of 17.31% and a 3-year CAGR of 13.37%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Ajanta Pharma Ltd.?

The latest trailing twelve month net profit (PAT) of Ajanta Pharma Ltd. is ₹ 1,056.00 Cr, with a 3-year earnings CAGR of 22.57%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Ajanta Pharma Ltd.?

The trailing twelve month EBITDA of Ajanta Pharma Ltd. is approximately ₹ 1,221.69 Cr (based on an operating margin of 22.40%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Ajanta Pharma Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Ajanta Pharma Ltd. is 84.51. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Ajanta Pharma Ltd.?

The debt-to-equity ratio of Ajanta Pharma Ltd. stands at 0.06. The interest coverage ratio is 75.83x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Ajanta Pharma Ltd.?

The estimated book value per share of Ajanta Pharma Ltd. is 362.35 (derived from a P/B ratio of 9.05 and market price of ₹ 3,278.80), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Ajanta Pharma Ltd.?

The trailing twelve month operating cash flow of Ajanta Pharma Ltd. is ₹ 561.76 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Ajanta Pharma Ltd. report consolidated or standalone financials?

Ajanta Pharma Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.